Estrogen receptor β is involved in acquired resistance to egfr-Tyrosine kinase inhibitors in lung cancer

Hiroki Sugiura, Yasuhiro Miki, Erina Iwabuchi, Ryoko Saito, Katsuhiko Ono, Ikuro Sato, Yoshinori Okada, Hironobu Sasano

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: Acquired resistance to epidermal growth factor receptor-Tyrosine kinase inhibitors (EGFR-TKIs) has posed serious clinical problems in the treatment of lung adenocarcinoma (LADC) patients harboring relevant EGFR mutations. In this study, we explored the role of estrogen receptor β (ERβ) in the development of acquired resistance to EGFR-TKIs in human LADC. Materials and Methods: First, the role of ERβ in erlotinib resistance of LADC cell lines (PC9/ER) was examined. Then, the immunolocalization of ERβ in 28 LADC patient samples treated with EGFR-TKIs was investigated. Results: Cytoplasmic ERβ was upregulated in erlotinib resistant cell lines. EGFR-TKIs sensitivity increased with ERβ inhibition in PC9/ER cells. ERK1/2 and AKT activities were both markedly increased by specific ERβ agonists even under erlotinib treatment of PC9/ER cells. Cytoplasmic ERβ immunoreactivity was significantly associated with clinical response to EGFR-TKIs. Conclusion: Cytoplasmic ERβ in LADC cells was involved in the development of resistance to EGFR-TKIs.

Original languageEnglish
Pages (from-to)2371-2381
Number of pages11
JournalAnticancer research
Volume41
Issue number5
DOIs
Publication statusPublished - 2021 May

Keywords

  • EGFR tyrosine kinase inhibitor
  • Estrogen receptor β
  • drug resistance
  • lung cancer.

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Estrogen receptor β is involved in acquired resistance to egfr-Tyrosine kinase inhibitors in lung cancer'. Together they form a unique fingerprint.

Cite this